The mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma.

Purpose: We report the NGS-derived transcriptome profiling (paired-end RNA-seq) following proteasome inhibition in the multiple myeloma cell line MM.1S. Methods: MM.1S cells were treated for six hours with the synthetic proteasome inhibitor lactacystin or clinically-approved proteasome inhibitor bortezomib and RNA expression changes were quantified and compared to DMSO control-treated cells by RNA-sequencing. Overall design: MM.1S myeloma cells were profiled for gene expression after 6h of growth in the presence or the absence of lactacystin (6µM) or bortezomib (60 nM), using Illumina HiSeq 2500 high-throughput sequencing system.